AssayIndex

WWB-2512-S4435

Retatrutide · 5 mg declared · Wuhan Wansheng Biotechnology Co., Ltd. · manufactured 08 Dec 2025

CHARACTERISED
Lot code
WWB-2512-S4435
Supplier
WWB — Wuhan Wansheng Biotechnology Co., Ltd.
Compound
Retatrutide
Compound class
Incretin analogues and co-agonists
Declared label claim
5mg
Manufacture date
08 Dec 2025
Index quarter
2026-Q2
Independent assays
5
Laboratories involved
PeptideMeter, Medutest, VendorInvestigate, Janoshik
Provenance mix
Buyer-sourced ×1 · Supplier-supplied ×4
Section 1

Reproducibility across independent tests

Every report below is an observation of the same physical material. What they disagree about is measurement; what they agree about is the lot. The size of the disagreement is compared against what the contributing laboratories' own repeatability figures predict.

Independent assays 5
Median purity 98.40% n=5
Spread (max − min) 1.29pp n=5
Standard deviation 0.548pp n=5
95.196.096.897.798.699.4100.3This lot (WWB-2512-S4435)This lot (WWB-2512-S4435): Q1 98.37, median 98.40, Q3 99.11, n=5n=5All RetatrutideAll Retatrutide: Q1 97.75, median 98.41, Q3 98.87, n=496outlier 95.45outlier 95.54outlier 95.67outlier 95.97n=496 Purity (% area)
Figure 1. This lot's independent purity results against the whole Retatrutide record set in the index. The vertical line is the index acceptance specification for the incretin analogues and co-agonists class, 96.5 % area. A narrow box on the top row against a wide box on the bottom row is the ideal reading: it means the disagreement between lots is much larger than the disagreement within this one.
Section 2

Member reports 5

Every report the index holds on this lot. Each is a page carrying its own chromatogram, mass spectrum, mass balance, provenance and caveats.

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041402WWB-2512-S4435PeptideMeter2026-Q298.403.82Supplier-supplied1MARGINAL
AX-2026-041403WWB-2512-S4435Medutest2026-Q298.373.87Supplier-supplied1MARGINAL
AX-2026-041404WWB-2512-S4435PeptideMeter2026-Q299.114.5589.2Supplier-supplied2MARGINAL
AX-2026-041405WWB-2512-S4435VendorInvestigate2026-Q298.114.54Buyer-sourced1MARGINAL
AX-2026-041406WWB-2512-S4435Janoshik2026-Q299.404.0091.9Supplier-supplied1MARGINAL
Section 3

By laboratory

Where more than one laboratory assayed this lot, the difference between them is a paired observation of their relative bias — the same material, the same time window, different instruments. Those pairs are what the index's bias estimates are built from.

LaboratoryReportsPurity results (% area)MedianGradientPublished bias (pp)Bias-adjusted
PeptideMeter298.40, 99.1198.7528min-0.0598.80
Medutest198.3798.3725min+0.0898.29
VendorInvestigate198.1198.1132min-0.1198.22
Janoshik199.4099.4030min+0.0099.40

This lot contributes 6 paired comparisons to the inter-lab analysis.

Section 4

The supplier's certificate for this lot

One number the supplier wrote, beside the median of the numbers other people measured on the same physical material. That comparison is only available because the index groups by lot.

FigureSupplier COAThis reportIndex note
Purity (% area)99.3498.40divergence +0.94 pp vs batch median
Total impurities (% area)0.661.60
Largest single impurity (% area)not stated1.10
Water (%)2.13.82
Counter-ion (%)4.26.33
Peptide content (%w/w)93.1not determined
Endotoxin (EU/mg)0.47not determined
Method stated on certificateNOno method section — the result cannot be reconciled against any other
Section 5

Impurity fingerprint

The named impurities reported across this lot's assays, with how consistently each was seen. A fingerprint is what allows two lot numbers held by different companies to be identified as one bulk.

Named impurityReported inMedian % areaRange
[D-Aib2]-diastereomer5 / 50.370.15–1.10
aspartimide (−18 Da)5 / 50.090.05–0.11
truncated (5-39)5 / 50.020.01–0.04
C18 diacid regioisomer5 / 50.020.01–0.31
oxidised Trp (+16 Da)3 / 50.230.16–0.33
des-Aib20 analogue2 / 51.171.08–1.25
retatrutide dimer2 / 50.020.02–0.02
incomplete Fmoc removal (+222 Da)1 / 50.02
Section 7

What this rollup does not establish